Shift Bioscience is focused on developing innovative technologies aimed at reversing the effects of aging and addressing age-related diseases. The company has made significant advancements in gene-based interventions that rejuvenate human cells without inducing stem cell identity, which is a critical safety concern in therapeutic applications. Their AI platform has successfully identified six novel gene-based interventions that can reverse epigenetic aging, including a single-gene intervention. This platform also allows for extensive screening of small molecules and combinations to discover potential rejuvenation mechanisms, with the capability to test up to 2,000 molecules in vitro and over a billion combinations in silico.

In addition to their gene-based approaches, Shift Bioscience has established itself as a leader in cell simulations and aging clocks. The company utilizes advanced cell aging clocks, developed by their team of experts, to enhance the accuracy of their research and discovery processes. These tools enable the exploration of various interventions for cell rejuvenation, leveraging insights from single-cell transcriptomic data. The combination of their AI-driven simulations and precise aging clocks positions Shift Bioscience at the forefront of the biotechnology field, with the potential to significantly impact healthcare by developing first-in-class therapeutics for age-related conditions.

United Kingdom

Shift Bioscience is using simulation guided cell rejuvenation to defeat the diseases of aging. Cellular reprogramming with Yamanaka factors can reverse aging in the dish but is not yet safe for clinical use. Shift has pioneered the first high throughput and high accuracy aging biomarker, which has been leveraged inside AI-based cell simulations to identify safer rejuvenation gene-factors. Shift envisions the development of a single drug-family that can treat multiple diseases of aging, after which full and continued health into old age becomes the norm.

Shift Bioscience

Company Details